Immix Biopharma Inc. has released a presentation highlighting its developments in the treatment of relapsed/refractory AL amyloidosis. The presentation features clinical data presented at the American Society of Hematology $(ASH)$ meeting, focusing on the unmet needs of approximately 38,500 patients in the United States who currently face limited treatment options. The company emphasizes that there are no FDA-approved drugs for relapsed/refractory AL amyloidosis and that current second-line therapies yield low complete response rates. Immix Biopharma's investigational therapy, NXC-201, targets BCMA receptors on plasma cells, aiming to eliminate the source of toxic light chains responsible for organ damage in patients. The presentation also provides an overview of disease progression and the urgent need for more effective therapies. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief on January 09, 2026, and is solely responsible for the information contained therein.